Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426582 · ClinicalTrials.gov registry record · Phase 1
Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00426582 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT00426582, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone combined with carboplatin in adult patients with advanced solid tumors who progressed despite standard therapy or for whom no standard therapy exists or who might benefit from treatment with carboplatin
Interventions
- DRUG Patupilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00426582
The ClinicalTrials.gov registry entry for NCT00426582 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patupilone is the first listed.
NCT00426582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00426582 about?
NCT00426582 is a clinical study titled "Combination Trial of Patupilone and Carboplatin in Adult Patients With Advanced Solid Tumors". This study will evaluate the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of patupilone combined with carboplatin in adult patients with advanced solid tumors who progressed despite standard therapy or for whom no standard therapy exists or who might benefit from treatment with carb...
What is the current status of trial NCT00426582?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-08.
What interventions are being tested in trial NCT00426582?
The interventions under investigation include: Patupilone (DRUG).
Who is sponsoring clinical trial NCT00426582?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.